期刊
CANCERS
卷 14, 期 5, 页码 -出版社
MDPI
DOI: 10.3390/cancers14051263
关键词
non-small-cell lung cancer; lobectomy; pneumonectomy; sublobar resection; surgery; enhanced recovery pathways; thoracoscopy; video-assisted thoracoscopic surgery; robotic-assisted thoracic surgery
类别
The management strategy for non-small-cell lung cancer (NSCLC) has changed due to advancements in cancer biology and the development of novel systemic therapies. Surgical resection remains the best option for cure or disease control, with reduced morbidity due to improved techniques. Patient-centered discussions and promising therapies like immune checkpoint inhibitors have improved outcomes. The field of thoracic oncology has rapidly evolved, with the expansion of indications for surgery to include advanced and metastatic disease. Careful patient selection and timing of multi-modality therapy are crucial.
The management strategy for the treatment of non-small-cell lung cancer (NSCLC) has been transformed by our improved understanding of the cancer biology and concomitant development of novel systemic therapies. Complete surgical resection of NSCLC continues to offer the best chance for cure or local and regional disease control, and with improvements in minimally invasive techniques and enhanced recovery, the morbidity associated with surgical resection has been reduced. Patient-centered multi-disciplinary discussions that consider surgical therapy are associated with improved outcomes. Provided with promising novel therapeutic modalities including immune checkpoint inhibitors with or without chemotherapy, stereotactic radiotherapy, and targeted systemic therapies, indications for surgery continue to evolve and have expanded to include selected patients with advanced and metastatic disease. With recent strides made within the field of thoracic oncology, the management of NSCLC is evolving rapidly. Careful patient selection and timing of multi-modality therapy to permit the optimization of therapeutic benefit must be pursued. While chemotherapy and radiotherapy continue to have a role in the management of lung cancer, surgical therapy remains an essential component of lung cancer treatment in early, locally and regionally advanced, as well as in selected, cases of metastatic disease. Recent and most impactful advances in the treatment of lung cancer relate to the advent of immunotherapy and targeted therapy, molecular profiling, and predictive biomarker discovery. Many of these systemic therapies are a part of the standard of care in metastatic NSCLC, and their indications are expanding towards surgically operable lung cancer to improve survival outcomes. Numerous completed and ongoing clinical trials in the surgically operable NSCLC speak to the interest and importance of the multi-modality therapy even in earlier stages of NSCLC. In this review, we focus on the current standard of care indications for surgical therapy in stage I-IV NSCLC as well as on the anticipated future direction of multi-disciplinary lung cancer therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据